Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial

Journal of Obstetrics and Gynaecology Research

Volumn 41, Issue 3, 2015, Pages 402-410

  Leelaphiwat, Supatra ^a   Jongwutiwes, Theerayut ^a   Lertvikool, Srithean ^a   Tabcharoen, Chotika ^a   Sukprasert, Matchuporn ^a   Rattanasiri, Sasivimol ^a   Weerakiet, Sawaek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

combined oral contraceptive pills; cyproterone acetate; desogestrel; polycystic ovary syndrome; spironolactone

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CHOLESTEROL; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; ANTIANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT;

ACNE; ADULT; ARTICLE; BREAST ENGORGEMENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEADACHE; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; LOW DRUG DOSE; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; VOMITING; WEIGHT GAIN; WITHDRAWAL BLEEDING; ACNE VULGARIS; BLOOD; COMBINATION DRUG THERAPY; COMPLICATION; METABOLISM; POLYCYSTIC OVARY SYNDROME; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ACNE VULGARIS; ADULT; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENEDIONE; CHOLESTEROL; CONTRACEPTIVES, ORAL, SYNTHETIC; CYPROTERONE ACETATE; DESOGESTREL; DRUG THERAPY, COMBINATION; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPERANDROGENISM; LIPOPROTEINS, HDL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POLYCYSTIC OVARY SYNDROME; SEVERITY OF ILLNESS INDEX; SEX HORMONE-BINDING GLOBULIN; SPIRONOLACTONE; YOUNG ADULT;

EID: 84924762599     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12543     Document Type: Article

References (47)

1. Norman RJ, Dewailly D, Legro RS, Hickey TE,. Polycystic ovary syndrome. Lancet 2007; 370: 685-697.
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011.
3. Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: A large community-based study. Hum Reprod 2013; 28: 2562-2569.
4. Dunaif A,. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
5. Holte J,. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996; 10: 221-247.
6. Lowenstein EJ,. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther 2006; 19: 210-223.
7. Lee AT, Zane LT,. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007; 8: 201-219.
8. Weerakiet S, Tingthanatikul Y, Boonnag P, Wansumrith S, Rattanasiri S, Leelaphiwat S,. Can adiponectin predict abnormal glucose tolerance in Thai women with polycystic ovary syndrome? J Obstet Gynaecol Res 2008; 34: 55-61.
9. Moura HH, Costa DL, Bagatin E, Sodre CT, Manela-Azulay M,. Polycystic ovary syndrome: A dermatologic approach. An Bras Dermatol 2011; 86: 111-119.
10. Katsambas AD, Dessinioti C,. Hormonal therapy for acne: Why not as first line therapy? facts and controversies. Clin Dermatol 2010; 28: 17-23.
11. Evans DJ, Burke CW,. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. J R Soc Med 1986; 79: 451-453.
12. Sato K, Matsumoto D, Iizuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg 2006; 30: 689-694.
13. George R, Clarke S, Thiboutot D,. Hormonal therapy for acne. Semin Cutan Med Surg 2008; 27: 188-196.
14. Yemisci A, Gorgulu A, Piskin S,. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 2005; 19: 163-166.
15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group,. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
16. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
17. Doshi A, Zaheer A, Stiller MJ,. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 1997; 36: 416-418.
18. Hatch R, Rosenfield RL, Kim MH, Tredway D,. Hirsutism: Implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815-830.
19. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H,. Position statement: Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405-413.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
21. De Leo V, Fruzzetti F, Musacchio MC, Scolaro V, Di Sabatino A, Morgante G,. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception 2013; 88: 364-368.
22. Di Carlo C, Gargano V, Sparice S, Tommaselli GA, Bifulco G, Nappi C,. Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: An observational preliminary study. Gynecol Endocrinol 2013; 29: 1048-1050.
23. Vieira CS, Martins WP, Fernandes JB, et al. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception 2012; 86: 268-275.
24. Harmanci A, Cinar N, Bayraktar M, Yildiz BO,. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013; 78: 120-125.
25. Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M,. Body composition is improved during 12 months treatment with metformin alone or combined with oral contraceptives compared to treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99: 2584-2591.
26. Kahraman K, Sukur YE, Atabekoglu CS, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: A randomized clinical trial. Arch Gynecol Obstet 2014; 290: 321-328.
27. Hong JS, Kwon HH, Park SY, et al. Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients. J Eur Acad Dermatol Venereol 2014 Mar 14. doi: 10.1111/jdv.12432.
28. Mastorakos G, Koliopoulos C, Creatsas G,. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002; 77: 919-927.
29. Cagnacci A, Paoletti AM, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 2003; 88: 3621-3625.
30. Archer JS, Chang RJ,. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 737-754.
31. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R,. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69: 2-15.
32. Thorneycroft H, Gollnick H, Schellschmidt I,. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74: 123-130.
33. Kerscher M, Reuther T, Bayrhammer J, Schramm G,. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: An open-label, single-centre, phase IV study. Clin Drug Investig 2008; 28: 703-711.
34. Plewig G, Cunliffe WJ, Binder N, Hoschen K,. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: A randomized, double-blind, placebo-controlled Phase III trial. Contraception 2009; 80: 25-33.
35. Kelekci KH, Kelekci S, Yengel I, Gul S, Yilmaz B,. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens. J Dermatolog Treat 2012; 23: 177-183.
36. Kelestimur F, Sahin Y,. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril 1998; 69: 66-69.
37. Karakurt F, Sahin I, Guler S, et al. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study. Adv Ther 2008; 25: 321-328.
38. Inal MM, Yildirim Y, Taner CE,. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: A randomized controlled study. Fertil Steril 2005; 84: 1693-1697.
39. Kebapcilar L, Bilgir O, Alacacioglu A, et al. Impaired hypothalamo-pituitary-adrenal axis in patients with ankylosing spondylitis. J Endocrinol Invest 2010; 33: 42-47.
40. Villaseca P, Hormaza P, Cardenas I, Oestreicher E, Arteaga E,. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: Lipid and carbohydrate changes. Eur J Contracept Reprod Health Care 2004; 9: 155-165.
41. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G,. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006; 85: 420-427.
42. Mes-Krowinkel MG, Louwers YV, Mulders AG, de Jong FH, Fauser BC, Laven JS,. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertil Steril 2014; 101: 1757-1765.e1.
43. Bozdag G, Yildiz BO,. Combined oral contraceptives in polycystic ovary syndrome-indications and cautions. Front Horm Res 2013; 40: 115-127.
44. Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28: 49-53.
45. Creatsas G, Koliopoulos C, Mastorakos G,. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci 2000; 900: 245-252.
46. Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R,. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69: 271-278.
47. Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S,. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990; 69: 61-65.